Steven Leonard Chapman Sells 2,662 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) CEO Steven Leonard Chapman sold 2,662 shares of Natera stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $90.42, for a total transaction of $240,698.04. Following the transaction, the chief executive officer now directly owns 234,526 shares in the company, valued at $21,205,840.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

  • On Friday, March 15th, Steven Leonard Chapman sold 83,223 shares of Natera stock. The stock was sold at an average price of $88.96, for a total transaction of $7,403,518.08.
  • On Tuesday, March 5th, Steven Leonard Chapman sold 9,326 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $824,045.36.
  • On Monday, January 29th, Steven Leonard Chapman sold 14,813 shares of Natera stock. The stock was sold at an average price of $65.09, for a total transaction of $964,178.17.
  • On Monday, January 22nd, Steven Leonard Chapman sold 1,958 shares of Natera stock. The stock was sold at an average price of $68.16, for a total transaction of $133,457.28.

Natera Stock Performance

NTRA stock opened at $91.46 on Friday. The company has a market capitalization of $11.04 billion, a P/E ratio of -24.13 and a beta of 1.39. The company has a 50-day simple moving average of $78.46 and a 200 day simple moving average of $61.30. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $96.24. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRAGet Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. Sell-side analysts predict that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. RiverPark Advisors LLC acquired a new stake in Natera in the fourth quarter worth about $27,000. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in Natera in the second quarter worth about $29,000. Principal Securities Inc. acquired a new stake in Natera in the 4th quarter valued at about $32,000. Pinebridge Investments L.P. acquired a new stake in Natera in the 2nd quarter valued at about $33,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Natera in the 3rd quarter valued at about $44,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Natera from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. Piper Sandler lifted their price target on shares of Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Thursday, March 14th. Raymond James lowered shares of Natera from a “strong-buy” rating to an “outperform” rating and lifted their price target for the stock from $68.00 to $85.00 in a research note on Tuesday, February 20th. Finally, BTIG Research lifted their price target on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $78.36.

View Our Latest Stock Report on Natera

Natera Company Profile

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Further Reading

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.